Biocon Biologics Expands Strategic Partnership with Civica for Affordable US Insulin Supply

Biocon Biologics, a subsidiary of Biocon Ltd., announced a significant extension of its strategic multi-year agreement with the US non-profit organization, Civica Inc., establishing an exclusive distribution channel to enhance access to affordable insulins and other pharmaceutical products across the United States. Under this expanded partnership, Biocon Biologics will manufacture and supply its Insulin Glargine medicine to Civica. Critically, Civica will manage all US sales, promotion, and distribution. The new medicine will be sold under Civica's branding across the majority of the US, with the exception of California, where it will be marketed under the CalRx brand. This collaboration is distinct from Biocon Biologics’ existing commercialization efforts, as the company confirmed it will continue to market and sell its FDA-approved branded Insulin Glargine-yfgn (Semglee) separately. Biocon Biologics retains full ownership of the intellectual property and marketing authorization for Insulin Glargine, with no technology transfer involved in this agreement. CEO and Managing Director Shreehas Tambe highlighted that the partnership enables Biocon Biologics to leverage new channels to reach underserved populations, aligning with the company's mission to enhance patient access. Civica's President and CEO, Ned McCoy, noted the agreement supports their goal of making insulin widely accessible and affordable. This strategic distribution deal is expected to strengthen Biocon Biologics’ US sales, bolstering its presence in a market where it has secured four FDA approvals in the last ten months and operates with a portfolio of nine products, targeting a $7 billion global opportunity. The dual-channel approach—retaining branded commercialization alongside the high-volume, mission-driven Civica partnership—underscores a differentiated strategy for market penetration and maximizing patient reach.